Cheplapharm
TypeGesellschaft mit beschränkter Haftung (GmbH)
IndustryPharmaceutical
FoundedJuly 1998[1]
HeadquartersMesekenhagen, Germany
Area served
Worldwide
Key people
  • Sebastian F. Braun (CEO)
  • Bianca Y. Juha (CSO)
  • Edeltraud Lafer (COO)
  • Jens Rothstein (CFO)[2]
Productsprescription medications
over-the-counter drugs and other medical products
RevenueEuro 223 million[3] (2017)
Number of employees
500[1] (July 2021)
ParentBraun Beteiligungs GmbH[4]
Websitewww.cheplapharm.com
Cheplapharm building in a business park in Greifswald

Cheplapharm Arzneimittel GmbH, headquartered in Greifswald, is a German pharmaceutical company that markets branded drugs, medical products, supplements and cosmetics.

Cheplapharm is among the most notable small and medium-sized enterprises (SME) in the federal state of Mecklenburg-Western Pomerania,[5][6] and part of Braun Beteiligungs GmbH,[4] a family owned business conglomerate that is among that state's 25 biggest employers.[7][8] Subsidiaries of the company are located in Hamburg, Levallois-Perret (France) and Englewood, New Jersey.

Cheplapharm acts as a divestment partner for various large pharmaceutical companies.[9][10][11][12] Since its foundation in 1998, Cheplapharm has acquired exclusive rights for more than 80 drugs and other pharmaceutical products that their developers intended to divest for economic or strategic reasons, generating yearly double-digit growth rates with this international “buy and build“ strategy. As of 2018, the company holds more than 400 pharmaceutical product registrations in over 120 countries worldwide.[3]

History

The company was founded 1998 in Freiburg by Kurt Teubner, who had been working as a manager for Ciba Geigy (now Novartis). The name Cheplapharm derives from the plant based diuretic Cheplaren,[13] one of the first products Teubner acquired.[14]

In 2003, Cheplapharm was bought by the Braun family. The new proprietors moved operations to Mesekenhagen, where Norbert and Dagmar Braun owned another pharmaceutical company, Riemser AG, a spin-off of the Friedrich Loeffler Institute.[15] Their son Sebastian F. Braun assumed the CEO position at Cheplapharm.[14]

Over the years, Cheplapharm has acquired the rights to more than 80[16] branded pharmaceuticals and medical products from multinational and German pharmaceutical companies. Among them are large corporations like Merck, F. Hoffmann-La Roche, AstraZeneca, Sanofi, Boehringer Ingelheim and Johnson & Johnson as well as midsize businesses like Grünenthal, Klosterfrau or Riemser.[9] Key acquisitions were those of Heminevrin/Distraneurin (a sedative used to treat acute alcohol withdrawal), from AstraZeneca, in 2010,[11] Rohypnol (a hypnotic) and Vesanoid (a leukemia medication, both from F. Hoffmann-La Roche, in 2012), Deursil/Ursolvan (an anti-gallstone medication, from Sanofi in 2014), Dilatrend (a beta blocker), Xenical (an anti-obesity medication) and Anexate (a benzodiazepine antagonist, all three from F. Hoffmann-La Roche[12] in 2016),[17][18][19] Konakion and Cymevene (a vitamin K supplement and a virostatic, from F. Hoffmann-La Roche in 2018),[20] Visudyne (a photosensitizer used for photodynamic therapy of the wet form of macular degeneration, from Novartis in 2018) and Sotacor/Sotalex (an antiarrhythmic, from Bristol-Myers Squibb in 2018).[21][1]

In 2017, Cheplapharm signed a distributorship agreement with an Orexigen Therapeutics subsidiary to market Mysimba, a combination drug for weight loss, in Germany, France and Austria.[22] Cheplapharm also markets several over-the-counter remedies of local renown or niche appeal in Germany. Among them are Reisegold (an antiemetic with Dimenhydrinate, marketed specifically for motion sickness), the valerian extract-based sedative Baldrian Dispert, and a number of herbal tinctures from the 'Thüringer' brand formerly owned by Klosterfrau.[1]

Cheplapharm has expanded its operations by taking over the pharma companies Walter Ritter GmbH & Co., Hamburg (2008), Sanavita Pharmaceuticals, Werne (2012) and Glenwood LCC, New Jersey[23] (2014). The latter company's main product is Potaba, an urological drug.[1] The French subsidiary Cheplapharm France SAS, located in Levallois-Perret, was established in 2016.[24]

In 2017, Cheplapharm founded a joint venture with the German medical technology company Clearum. The venture, by the name of Med-Tec Holding GmbH, is meant to focus on manufacture of medical technology products, research and development.[25][26][27][28] Construction of a new production facility near Rostock has been announced to start in July 2018.[29]

In 2020, the company invested in product portfolios from Takeda and Leo Pharma.[30] The Takeda portfolio, which comprises 17 products, was the company's largest acquisition to date in terms of scope and purchase price (EUR 450 million).[31][32] In 2021, all rights to the epilepsy drug Rivotril were acquired from Roche, and Astellas took over the approvals for four branded antibiotics and De Nol,[33] a drug against Helicobacter pylori infections, for Russia, Ukraine and other CIS countries.[34]

Products

Cheplapharm owns global or local marketing and distribution rights for a number of prescription drugs that are used in cardiology (Dilatrend, Aldactone, Inhibace, Sotalex/Sotacor, Pertenso, Dopegyt, Natrilix, Vascal), haematooncology (Vesanoid), urology (Potaba), gastroenterology and bariatrics (Deursil/Ursolvan, Cotazym, Xenical, Mysimba), emergency medicine (Anexate), addiction medicine (Heminevrin/Distraneurin), sleep medicine (Rohypnol, Aponal), infection control (Cymevene, Lariam) and ophthalmology (Visudyne).

The company also markets over-the-counter drugs for common health issues (e.g. antiemetics, antacids, antidiarrhoeals, cardiovascular remedies, painkillers, sedatives) and medical products, among them dietary supplements, hot-cold-packs, cold sprays and dermatological care products.[16]

References

  1. 1 2 3 4 5 "At a glance" (PDF). cheplapharm.com. Archived from the original (PDF) on 2018-10-13. Retrieved 2018-10-11.
  2. ↑ "Imprint". cheplapharm.com. Retrieved 2018-10-11.
  3. 1 2 "Factsheet" (PDF). cheplapharm.com. Archived from the original (PDF) on 2018-10-13. Retrieved 2018-10-11.
  4. 1 2 "Shareholdings – Pharmaceutical sector". braun-beteiligungen.de. Retrieved 2018-10-11.
  5. ↑ "Pharmafirma investiert 210 Millionen Euro" [Pharmaceutical company to invest 210 Mio. Euro]. ostsee-zeitung.de (in German). 2017-09-01. Archived from the original on 2018-10-13. Retrieved 2018-10-11.
  6. ↑ Lothar Klein (2017-09-01). "Merkel bei Cheplapharm" [Merkel visits Cheplapharm]. apotheke-adhoc.de (in German). Retrieved 2018-10-11.
  7. ↑ "Die 100 größten Unternehmen in Mecklenburg-Vorpommern" [The 100 largest companies in Mecklenburg-Vorpommern] (PDF). lfi-mv.de (in German). 2017-12-01. Archived from the original (PDF) on 2018-10-13. Retrieved 2018-10-11.
  8. ↑ Cornelia Meerkatz (2016-11-25). "Die Erfolgs-Familie. Mit Medizin, Mode und Wurst macht die Greifswalder Braun-Gruppe Hunderte Millionen Euro Umsatz" [A successful family. Greifswald-located Braun Group's revenues from pharma, fashion and sausage reach hundreds of millions of euros]. ostsee-zeitung.de (in German). Archived from the original on 2018-10-13. Retrieved 2018-10-11.
  9. 1 2 "Business development" (PDF). cheplapharm.com. Archived from the original (PDF) on 2018-10-13. Retrieved 2018-10-11.
  10. ↑ "Ich bin ein Schattenbanker" [I am a shadow banker]. sueddeutsche.de (in German). 2017-09-06. Retrieved 2018-10-11.
  11. 1 2 "AZ grants clomethiazole rights to Cheplapharm". scrip.pharmaintelligence.informa.com. 2016-08-01. Retrieved 2018-10-11.
  12. 1 2 "Cheplapharm gets rights to two drugs from Roche". scrip.pharmaintelligence.informa.com. 2016-08-01. Retrieved 2018-10-11.
  13. ↑ Barschneider, M. (February 1959). "[Cheplaren, a plant extract diuretic]". Dtsch Med J. (in German). 10 (3): 63–67. PMID 13639739.
  14. 1 2 Patrick Holstein (2015-02-04). "Riemser reloaded". apotheke-adhoc.de (in German). Retrieved 2018-10-12.
  15. ↑ Patrick Holstein. "Riemser Arzneimittel AG: Auf Expansionskurs mit spezialisiertem Beteiligungskapital" [Riemser Pharma AG: On a course of expansion with specialized equity capital]. bvkap.de (in German). Retrieved 2018-10-12.
  16. 1 2 "Produkte von A bis Z" [Our products from A to Z]. cheplapharm.com (in German). Retrieved 2018-10-12.
  17. ↑ "Largest private sector investment in Mecklenburg-Western Pomerania: CHEPLAPHARM makes the megadeal". cheplapharm.com. 2016-10-27. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  18. ↑ "Cheplapharm acquires product rights for Anexate® from F. Hofmann-La Roche". cheplapharm.com. 2016-01-20. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  19. ↑ "Cheplapharm hat bei den Großen eingekauft" [Cheplapharm has shopped the big name companies]. ostsee-zeitung.de (in German). 2016-01-09. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  20. ↑ "Cheplapharm continues its expansion course and complements its portfolio with four further products". cheplapharm.com. 2018-01-26. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  21. ↑ "Cheplapharm further enhances its portfolio in the Cardiology area". cheplapharm.com. 2018-08-05. Archived from the original on 2018-10-13. Retrieved 2018-10-12.
  22. ↑ "Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria". prnewswire.com. 2018-08-07. Retrieved 2018-10-12.
  23. ↑ "Glenwood, LCC". Archived from the original on 2018-10-01. Retrieved 2018-10-12.
  24. ↑ "Cheplapharm France". societe.com. Retrieved 2018-10-12.
  25. ↑ Paolo Bossi (2017-10-28). "Clearum GmbH and Cheplapharm Arzneimittel GmbH estabilishes [sic] Med-Tec Holding GmbH". globallegalchronicle.com. Retrieved 2018-10-12.
  26. ↑ "Pharma- und Medizintechnikfirma gründen neues Unternehmen" [Pharma und medical technology companies found new enterprise]. aerzteblatt.de (in German). 2017-10-20. Retrieved 2018-10-12.
  27. ↑ "Mit Medizintechnik auf den Weltmarkt" [Medical technology for the global market]. nnn.de (in German). 2017-10-21. Retrieved 2018-10-12.
  28. ↑ "Pharma- und Medizintechnikfirma gründen neues Unternehmen" [Pharma und medical technology companies found new enterprise]. welt.de (in German). 2017-10-20. Retrieved 2018-10-12.
  29. ↑ "Dialyse-Filter für China: In Laage entsteht neues Werk" [Dialysis filters for China: New plant to be built in Laage]. ostsee-zeitung.de (in German). 2018-05-24. Retrieved 2018-10-12.
  30. ↑ "LEO Pharma sells four non-core products to Cheplapharm". www.thepharmaletter.com. Retrieved 2022-08-19.
  31. ↑ "Detail|Cheplapharm Greifswald". 2021-01-25. Archived from the original on 2021-01-25. Retrieved 2022-08-19.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  32. ↑ "Cheplapharm kauft mit Latham Wirkstoffe von Takeda und Leo Pharma". juve.de (in German). 2020-09-14. Retrieved 2022-08-19.
  33. ↑ "Greifswald: Cheplapharm sichert sich Rechte an Epilepsie-Medikament Rivotril". www.ostsee-zeitung.de (in German). Retrieved 2022-08-19.
  34. ↑ "Astellas divest legacy products to Cheplapharm; drops vaccine candidat". www.thepharmaletter.com. Retrieved 2022-08-19.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.